Details

Autor(en) / Beteiligte

• Swords, Ronan T., MD, PhD
• Greenberg, Peter L., MD
• Wei, Andrew H., MBBS, PhD
• Durrant, Simon, MBBS
• Advani, Anjali S., MD
• Hertzberg, Mark S., MBBS, PhD
• Lewis, Ian D., MBBS, PhD
• Rivera, Gabriel, MD
• Gratzinger, Dita, MD, PhD
• Fan, Alice C., MD
• Felsher, Dean W., MD, PhD
• Cortes, Jorge E., MD
• Watts, Justin M., MD
• Yarranton, Geoff T., PhD
• Walling, Jackie M., MB, ChB, PhD
• Lancet, Jeffrey E., MD

Titel

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]

Ist Teil von

• Leukemia research, 2017-08, Vol.59, p.65-65

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2017

Quelle

Alma/SFX Local Collection